Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung

NCT07202260 | Active Not Recruiting

• 1 other identifier: CFTSP 230
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

This study focuses on improving care for people with lung cancer who face unusual or complex treatment situations.

Conditions

Lung Cancer (NSCLC); Lung Cancer (SCLC)

Keywords

radiotherapy; interstitial lung disease; vascular invasion; re-irradiation; rare histology

Outcome Measures

Primary Outcomes (1)

• Acute and late toxicity

  \- Acute (\<90 days post radiotherapy) and late (\> 90 days post radiotherapy) toxicity according to common terminology criteria for adverse events (CTCAE) V5.

  2 years

Other Outcomes (2)

• Patient reported quality of life

  2 years

• Survival

  2 years

Study Arms (5)

Patients with co-existing interstitial lung disease

Patients who undergo radiotherapy twice to the same area (reirradiation).

Patients with the less common or rare types of lung cancer

Patients with cancer invading large blood vessels.

Patients with oligopersistent/oligoprogressive disease on immunotherapy or targeted therapies.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients over 18 years of age, with stage I, II or III lung cancer undergoing curative-intent radiotherapy at the Christie Hospital.

You may qualify if:

• Rare histology
• Disease invading vascular structures
• Co-existing interstitial lung disease (ILD)
• Radical re-irradiation
• Oligopersistent/oligoprogressive disease on immunotherapy or targeted therapies.

You may not qualify if:

• Include patients with stage IV disease who are receiving non-curative intent radiotherapy

Sponsors & Collaborators

• The Christie NHS Foundation Trust: lead

Study Sites (1)

The Christie NHS Foundation Trust

Withington, Greater Manchester, M20 1BX, United Kingdom

Location

MeSH Terms

Conditions

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Diseases, Interstitial

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 2 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 20, 2025
• First Posted: October 1, 2025
• Study Start: July 3, 2025
• Primary Completion (Estimated): July 15, 2028
• Study Completion (Estimated): December 1, 2028
• Last Updated: October 1, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)